

2007

February

Roy. Pharmaceutical Soc. of Great Britain
Stability Testing of Pharmaceuticals
Feb. 19-21, Cambridge, UK
www.rpsgb.org

PITTCON 2007
Feb. 25 – Mar. 2, Chicago, IL
www.pittcon.org

March

Amer. Col. of Legal Med.
47th Conf. on Legal Med.
Mar. 1-4, Orlando, FL • www.aclm.org

Biophysical Soc.
51st Ann. Mtg. • Mar. 3-7, Baltimore, MD
www.biophysics.org

Banff2007 - Pharmacology &
Therapeutics Conf.
Mar. 4-8, Banff, Alberta, Canada
www.westernpharmsoc.org/
meeting2007.html

Amer. Assn. Pharmaceutical Scientists
Workshop on Poorly Soluble Drugs
Mar. 5-6, Bethesda, MD
www.aapspharmaceutica.com/Lipids

Cambridge Healthtech Institute
3rd Ann. Business of Translational Med.
Mar. 6-7, Philadelphia, PA
www.healthtech.com

Nat. Ctr. on Addiction & Substance
Abuse at Columbia Univ. • Compound
Fractures: Substance Abuse & Trauma
Mar. 8, 2007, New York City, NY
www.casacolumbia.org

Winter Eicosanoid Conference
9th Ann. Conf.
Mar. 11-14, Baltimore, MD
www.nymc.edu/eicosanoid

Roy. Pharmaceutical Soc. of Great Britain
Arden House European Conf.
Mar. 12-14, London, UK • www.rpsgb.org

Amer. Coll. of Osteopathic
Family Physicians • 44th Ann. Conv.
Mar. 14-18, Kissimmee, FL
www.acofp.org

8th Int. Conf. on Alzheimer's &
Parkinson's Diseases
Mar. 14-18, Salzburg, Austria
www.kenes.com/adpd

Amer. Soc. for Clinical Pharmacology &
Therapeutics • 108th Ann. Mtg.
Mar. 21-24, Anaheim, CA
www.ascpt.org

Soc. of Toxicology • 46th Ann. Mtg.
Mar. 25-29, Charlotte, NC
www.toxicology.org/2007

Assn. of Biomolecular Resource Facilities
Mar. 31 – Apr. 3, Tampa, FL
www.faseb.org/meetings

April

Minority Health Professions Foundation
21st Ann. Symp. on Career Opportunities
in Biomed. Sciences & Hlth. Professions
Apr. 4-7, Orlando, FL
www.minorityhealth.org

Phytochemical Soc. of Europe
50 Yrs. of the Phytochem. Soc. of Europe
Apr. 11-14, Cambridge, UK
www.pse50.com

Amer. Assn. for Cancer Res.
Ann. Mtg. 2007 • Apr. 14-18, Los
Angeles, CA • www.aacr.org

World Events Forum
Alzheimer's Disease: From Molecular
Mechanisms to Drug Discovery
Apr. 17-20, Punta Cana,
Dominican Republic
www.worldeventsforum.com/ad

Amer. Col. of Clin. Pharmacy
Spring Practice & Res. Forum
Apr. 21-25, Memphis, TN
www.accp.com

Pharma. Sciences World Congr.
Apr. 22-25, Amsterdam, The Netherlands
www.fip.org/PSWC

Experimental Biology 2007
AAA, APS, ASBMB, ASIP, ASN, ASPET
Apr. 28 – May 2, Washington, DC
www.faseb.org/meetings

Amer. Col. of Clinical Pharmacology
19th Frontiers Symp.
April 30 – May 1, Baltimore, MD
www.accp1.org

May

Amer. Col. of Clinical Pharmacology
QTC Cardiovascular Safety Symp.
May 2, Baltimore, MD
www.accp1.org

IXth Int. Mtg. on Cholinesterases
May 6-10, Suzhou, China
http://ihome.ust.hk/~ixche

Org. for the Study of Sex Differences
1st Ann. Mtg. • May 9-12, Washington, DC
www.ossdweb.org

Amer. Assn. of Immunologists
Immunology 2007
May 18-22, Miami Beach, FL
www.faseb.org/meetings

IBC Life Sciences
Oligonucleotide & Peptide Technology &
Product Development
May 20-23, Las Vegas, NV
www.ibclifesciences.com/tides

Roy. Pharmaceutical Soc. of Great Britain
9th Advanced Level Workshop on Pharma-
cokinetic-Pharmacodynamic Data Analysis
May 20-24, Cambridge, UK
www.rpsgb.org.uk

June

The Endocrine Soc. • Endo 2007
June 2-5, Toronto, Canada
www.endo-society.org

FASEB Summer Res. Confs.
Lysophospholipid Mediators in Health &
Disease • June 2-7, Tucson, AZ
src.faseb.org

FASEB Summer Res. Confs.
Proteases in Hemostasis & Vascular Biology
June 2-7, Indian Wells, CA
src.faseb.org

FASEB Summer Res. Confs.
Ion Channel Regulation
June 9-14, Snowmass Village, CO
src.faseb.org

Gordon Res. Conf.
Phosphorylation & G-Protein Mediated
Signaling Networks
June 10-15, Biddeford, ME
www.grc.org

European Science Foundation
Pharmacogenetics & Pharmacogenomics
June 15-20, Sant Feliu de Guixols, Spain
www.esf.org/conferences/07232

Int. Soc. for Stem Cell Res.
5th Ann. Mtg.
June 17-20, Cairns, Queensland, Australia
www.isscr.org

Drug Information Assn.
43rd Ann. Mtg. • June 17-21, Atlanta, GA
www.diahome.org

European Summer Schl. for Whole
Animal Pharmacology • ESSWAP 2007
Course on Behavioural Pharmacology
June 17-22, Oss, The Netherlands
www.esswap.org

FASEB Summer Res. Confs.
Signal Transduction in the Immune System
June 23-28, Snowmass Village, CO
src.faseb.org

July

FASEB Summer Res. Confs.
Protein Kinases & Protein Phosphorylation
July 7-12, Indian Wells, CA
src.faseb.org

FASEB Summer Res. Confs.
ARF Family GTPases
July 8-13, Lucca, Toscana, Italy
src.faseb.org

FASEB Summer Res. Confs.
The Biology of Calpains in Health & Disease
July 14-19, Snowmass Village, CO
src.faseb.org

Soc. of Toxicology of Canada & Nat.
Res. Council of Canada
11th Int. Congr. of Toxicology
July 15-19, Montreal, PQ, Canada
www.ict2007.org

FASEB Summer Res. Confs.
Neural Mechanisms in Cardiovascular
Regulation
July 18-23, Bondi Beach, Sydney, Australia
src.faseb.org

The Protein Soc.
21st Symp. • July 21-25, Boston, MA
www.faseb.org/meetings

Int. Acad. of Cardiology
13th World Congr. on Heart Disease
July 28-31, Vancouver, BC, Canada
www.cardiologyonline.com

August

13th Int. Conf. on 2nd Messengers &
Phosphoproteins • Aug. 1-4, San Diego,
CA • www.smp-2007.com

FASEB Summer Res. Confs.
Growth Factor Receptor Tyrosine
Kinases in Mitogenesis, Morphogenesis,
& Tumorigenesis • Aug. 11-12, Tucson, AZ
src.faseb.org

FASEB Summer Res. Confs.
Lipid Signaling Pathways in Cancer
Aug. 11-16, Indian Wells, CA
src.faseb.org

Amer. Psychological Assn. • 115th Conv.
Aug. 17-20, San Francisco, CA
www.apa.org

Dutch Soc. of Clinical Pharmacology &
Biopharmacy • 8th EACPT Congr. 2007
Aug. 29 – Sept. 1, Amsterdam, The
Netherlands • www.eacpt2007.nl

September

Amer. Col. of Clinical Pharmacology
36th Ann. Mtg. • Sept. 9-11, San
Francisco, CA • www.accp1.org

ASBMR • 29th Ann. Mtg.
Sept. 16-20, Honolulu, HI
www.asbmr.org

November

Amer. Soc. of Cytopathology
55th Ann. Scientific Mtg.
Nov. 2-7, Houston, TX
www.cytopathology.org

Soc. for Neuroscience • Ann. Mtg.
Nov. 3-7, San Diego, CA
www.sfn.org

Ann. Biomed. Res. Conf.
for Minority Students
Nov. 7-10, Austin, TX • www.abrcms.org

Int. Soc. of Cardiovascular Pharmacotherapy
14th Int. Cong. on Cardiovascular
Pharmacotherapy
Nov. 28 – Dec. 2, Antalya, Turkey
www.iscp2007.org

2008

April

Experimental Biology '08 & ASPET's
Centennial Celebration
Apr. 5-9, San Diego, CA
www.faseb.org/meetings

Amer. Assn. for Cancer Res.
Ann. Mtg. 2008
Apr. 18-22, San Diego, CA
www.aacr.org

June

World Conf. on Breast Cancer Foundation
5th World Conf. on Breast Cancer
June 4-8, Winnipeg, MB, Canada
www.wbcfc.ca

July

IXth World Conf. on Clinical
Pharmacology & Therapeutics - CPT 2008
July 27 – Aug. 1, Quebec City, Canada
www.cpt2008.org

August

Amer. Psychological Assn.
116th Conv. • Aug. 14-17, Boston, MA
www.apa.org

September

ASBMR • 30th Ann. Mtg.
Sept. 12-16, Montreal, Quebec, Canada
www.asbmr.org

November

Amer. Soc. of Cytopathology
56th Ann. Scientific Mtg.
Nov. 2-7, Orlando, FL
www.cytopathology.org

Ann. Biomed. Res. Conf. for Minority
Students • Nov. 5-8, Orlando, FL
www.abrcms.org

Soc. for Neuroscience • Ann. Mtg.
Nov. 15-19, Washington, DC
www.sfn.org

Instructions to Authors

Scope of Submitted Manuscripts

Papers published in **Molecular Interventions** are generally invited by the Editor after consideration of recommendations from the Editorial Advisory Board. Others who have an interest in writing for **Molecular Interventions** are encouraged to send proposals to the Editor. The proposal should include a detailed outline of the proposed article and a brief curriculum vitae. Articles in **Molecular Interventions** deal mainly with the current status of the subject under review. They are to be written clearly and concisely and should be intelligible to nonspecialists, with definitions of unfamiliar technical terms and explanations of difficult or controversial points included. At the same time, the review is to be sufficiently precise and detailed to command the attention and respect of experts in the field. Selective rather than exhaustive coverage of the literature is requested. Previous reviews of the subject and of related fields should be cited. Authors are asked to be critical of methods, results, and conclusions and to challenge accepted concepts where warranted. Conflicting points of view are to be presented objectively in good perspective. Deficiencies in the field may be pointed out and avenues for further work may be indicated. The usual length ranges between 8 and 12 printed pages, corresponding to about 24 to 36 manuscript pages. Diagrams, tables, and illustrations should be included to bring out new concepts and important relationships. The Art Director will work with the author to further develop graphics for the article. **All review article manuscripts will be peer-reviewed and edited prior to publication.**

Submission of Manuscripts

Submit three (3) collated hard copies of each manuscript (including illustrations) as well as an electronic version to

Dr. Harry B. Smith, Editor
Molecular Interventions
ASPET
9650 Rockville Pike
Bethesda, MD 20814-3995

telephone: 301-634-7790
fax: 301-634-7061
e-mail: hsmith@aspet.org

Diskettes produced on PC or Mac platforms are acceptable. Microsoft Word is preferred. Authors preparing diskettes on Macintosh computers should not use the Fast Save option. Other formats and files in ASCII can be used, but are not encouraged. Authors are encouraged to supply a digital copy of their illustrations. Image files should be submitted by e-mail or on zip disks (formatted for Mac or PC) or CDs; TIFF and EPS formats are strongly preferred. Illustrations created in Adobe Illustrator, Freehand, or Corel Draw should be saved in EPS format.

A completed copy of the **Molecular Interventions** Copyright Transfer form signed by the corresponding author should be included with the manuscript at the time of submission (a copy of the form is available online at www.molinterv.org). Submission of a manuscript amounts to assurance that it has received proper clearance from the author's company or institution, that it has not been copyrighted, published, or accepted for publication elsewhere, that it is not currently being considered for publication elsewhere, and that it will not be submitted elsewhere while under consideration by **Molecular Interventions**. The corresponding author is responsible for obtaining permission from the copyright owner to reproduce or modify figures and tables and to reproduce text (in whole or in part) from previous publications; permissions must allow electronic reproduction as well as print. A permissions request form is available from the editorial office. The signed permissions must be submitted with the manuscript and be identified as to the relevant item in the manuscript (e.g., "permissions for Fig. 1"). In addition, a statement indicating that the material is being reprinted with permission must be included in the relevant figure legend or table footnote of the manuscript. Reprinted text must be enclosed in quotation marks, and the permission statement must be included as running text or indicated parenthetically.

Manuscripts must be in English, typewritten and double spaced throughout, including references, tables, and figure legends, using only one side of 8 1/2 by 11 inch (ca. 216 by 280 mm) paper, with at least 1 inch (25 mm) margins, and the copies must be collated. Pages should not be stapled.

Organization of the Manuscript

Manuscripts should contain the following sections in the order listed. Each section should begin on a new page and all pages should be numbered consecutively.

1. *Title page.* This should contain the complete title of the article, the names of all authors, and full contact information for corresponding author (address, phone, fax, e-mail). A running title and at least five keywords should also be given.

2. *Abstract.* The abstract should be approximately 100 words, and should provide the context in which the topic of the article should be appreciated. The abstract should be intelligible to the general reader without reference to text. Reference citations are not permitted in abstracts, and nonstandard abbreviations should not be included.

3. *Body of manuscript.* It is highly recommended that the body be divided into conceptual sections, the first of which should be labeled INTRODUCTION and the last of which should be labeled CONCLUSIONS. Section headings should be given in all capital letters, subsection headings in standard title format, and sub-subsection headings in italics.

4. *Acknowledgments.* The Acknowledgments section is placed at the end of the text.

5. *References.* References are cited in the text by number. In the reference list, the references should be arranged in the order in which they are first cited in the text. The names of all authors should be given in the reference list. Abbreviations for journals should conform to the BIOSIS List of Serials (BioSciences Information Services of Biological Abstracts, Philadelphia, PA 19103). References to personal communications, unpublished observations, and papers submitted for publication are given in parentheses at the appropriate location in the text, not in the list of references. Only papers that have been officially accepted for publication may be cited as "in press" in the reference list. The authors are responsible for the accuracy of the references. The format for journal article, chapter, and book references is as follows:

1. Griffiths, R.R., Bigelow, G.E., and Liebson, I.A. Human coffee drinking: Reinforcing and physical dependence producing effects of caffeine. *J. Pharmacol. Exp. Ther.* **239**, 416-425 (1997).
2. Chernow, B. and O'Brian, J.T. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (Ziegler, M.G. and Lake, C.R. eds) pp 439-449, Williams & Wilkins, Baltimore (1984).
3. Tallarida, R.J. and Murray, R.B. *Manual of Pharmacologic Calculations with Computer Programs.* Springer-Verlag, New York (1987).

6. *Tables.* Each table must be on a separate page. The tables are numbered consecutively with Arabic numerals, and designed to fit the column or page size of the journal. A brief descriptive title is provided at the top of each table. General statements about the table follow the title in paragraph form. Footnotes to tables are referenced by italicized, lower case, superscript letters (a, b, c, etc.) and defined beneath the table.

7. *Legends for figures.* Figures are numbered consecutively with Arabic numerals, with each one displayed on a separate page. Legends must provide sufficient explanation for the reader to understand the figure independent of the text.

8. *Figures.* Submit illustrations as glossy photographs, original India-ink drawings, or high-resolution laser printer output. Lettering on figures should be large enough to be legible after reduction to single-column width of 21 picas (about 3.5 inches or 9 cm). Letter typesizes after reduction should be 6-8 points. Do not use varying letter typesizes within a single figure; use the same size or similar sizes throughout the drawing. All panels of a multipart figure should be provided on the same page. Although each of the manuscript copies should contain a complete set of figures, only the originals need be of the quality suitable for reproduction. In the case of halftones, three sets of photographs are required. If symbols are not explained on the face of the figure, only standard print characters may be used. The back of each figure should bear its number, the name of the first author, and the word TOP at the appropriate edge. Include figure titles in the legend and not on the figure itself. Photomicrographs and electron micrographs must be labeled with a magnification calibration in micrometers or Angstrom units. A statement concerning the magnification must appear in the figure legend.

9. *Author Photographs.* Supply a color glossy photograph of each author. Head size (top of head to bottom of chin) should be no smaller than 1.5 inches; also allow generous room on all sides for cropping. Write full name on back of photos; identify multiple authors as necessary. Digital images of approximately 4MB are acceptable.

10. *Additional images.* All authors are encouraged to submit images to be considered for use on the cover of **Molecular Interventions**. Cover images should be submitted as glossy (8x10) prints, transparencies or negatives, or as high-resolution digital files. Cover submissions should be accompanied by a 100-word description of the image. In addition, the title of each review article will be highlighted by an image selected by the editorial office; authors are encouraged to supply images with an appropriate caption for title treatment. Consult a recent issue of **Molecular Interventions** for examples.

Abbreviations, Drug Names, Gene Names, Etc.

All abbreviations and technical nomenclature should be explained in parentheses upon their first use in the text. Do not abbreviate terms (other than standard abbreviations) that are used less than three times in the text. Generic drug names are used in text, tables, and figures. Trade names may be given in parentheses following the first text reference, but should not appear in titles, figures, or tables. Whereas trade names are capitalized, generic or chemical names are not.